Adrenal Cortical Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenocarcinoma

MalaCards integrated aliases for Adrenal Cortical Adenocarcinoma:

Name: Adrenal Cortical Adenocarcinoma 12 15
Adrenal Cortex Adenocarcinoma 12
Adrenocortical Carcinoma 70


External Ids:

Disease Ontology 12 DOID:3959
UMLS 70 C0206686

Summaries for Adrenal Cortical Adenocarcinoma

Disease Ontology : 12 An adrenocortical carcinoma that originates in the cortex of the adrenal gland and derives from epithelial cells of glandular origin.

MalaCards based summary : Adrenal Cortical Adenocarcinoma, also known as adrenal cortex adenocarcinoma, is related to adrenal carcinoma and legius syndrome, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Adenocarcinoma is SPRY2 (Sprouty RTK Signaling Antagonist 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Streptozocin and Mitotane have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotype is Increased viability with nutlin-3.

Related Diseases for Adrenal Cortical Adenocarcinoma

Diseases related to Adrenal Cortical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adrenal carcinoma 10.0
2 legius syndrome 9.9 SPRY2 SPRY1
3 dyskeratosis congenita, autosomal dominant 3 9.8 RPS6KA6 RPS6KA1
4 coffin-lowry syndrome 9.7 RPS6KA6 RPS6KA1

Symptoms & Phenotypes for Adrenal Cortical Adenocarcinoma

UMLS symptoms related to Adrenal Cortical Adenocarcinoma:

fever; flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with nutlin-3 GR00123-A 8.62 BAD KCNK9

Drugs & Therapeutics for Adrenal Cortical Adenocarcinoma

Drugs for Adrenal Cortical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
Mitotane Approved Phase 3 53-19-0 4211
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Etoposide Approved Phase 3 33419-42-0 36462
Lenograstim Approved, Investigational Phase 3 135968-09-1
7 Antineoplastic Agents, Hormonal Phase 3
8 Antimitotic Agents Phase 3
9 Tubulin Modulators Phase 3
10 Keratolytic Agents Phase 3
11 Dermatologic Agents Phase 3
12 Podophyllotoxin Phase 3 518-28-5
13 Antibiotics, Antitubercular Phase 3
Liposomal doxorubicin Phase 3 31703
15 Anti-Bacterial Agents Phase 3
16 Etoposide phosphate Phase 3
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
Sodium citrate Approved, Investigational Phase 2 68-04-2
Tamoxifen Approved Phase 2 10540-29-1 2733526
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
acetic acid Approved Phase 2 64-19-7 176
Lactitol Approved, Investigational Phase 2 585-86-4 157355
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
Ipilimumab Approved Phase 2 477202-00-9
Pembrolizumab Approved Phase 2 1374853-91-4
nivolumab Approved Phase 2 946414-94-4
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
36 Gossypol Investigational Phase 2 303-45-7
Suramin Investigational Phase 2 145-63-1 5361
38 Citrate Phase 2
39 Estrogens Phase 2
40 Liver Extracts Phase 2
41 Estrogen Receptor Antagonists Phase 2
42 Estrogen Antagonists Phase 2
43 Estrogen Receptor Modulators Phase 2
44 Immunologic Factors Phase 2
45 Gossypol acetic acid Phase 2
46 retinol Phase 2
47 Retinol palmitate Phase 2
48 Contraceptive Agents Phase 2
Retinol acetate Phase 2 127-47-9 10245972
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Unknown status NCT00777244 Phase 3 MITOTANE
2 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
3 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
5 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
6 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Active, not recruiting NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
7 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
8 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
9 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
10 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
11 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
12 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
13 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
14 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
16 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
17 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
18 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
19 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
20 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
21 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
22 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
23 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
24 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
25 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
26 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
27 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
28 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
29 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
30 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
31 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
32 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
33 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
34 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
35 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
36 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
37 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
38 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
39 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
40 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab
41 A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
42 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
43 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
44 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
45 A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease Completed NCT00436657 Phase 1 CHPP of Cisplatin
46 A Phase 1b, Open-Label Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production Recruiting NCT04373265 Phase 1 Relacorilant;Pembrolizumab
47 A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Active, not recruiting NCT02637531 Phase 1 IPI-549 (eganelisib);Nivolumab
48 A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma Terminated NCT01832974 Phase 1 IL-13-PE
49 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
50 Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma Unknown status NCT00457587

Search NIH Clinical Center for Adrenal Cortical Adenocarcinoma

Genetic Tests for Adrenal Cortical Adenocarcinoma

Anatomical Context for Adrenal Cortical Adenocarcinoma

MalaCards organs/tissues related to Adrenal Cortical Adenocarcinoma:

Cortex, Adrenal Gland, Adrenal Cortex, Thyroid, Lymph Node, Prostate, Pituitary

Publications for Adrenal Cortical Adenocarcinoma

Articles related to Adrenal Cortical Adenocarcinoma:

(show top 50) (show all 2664)
# Title Authors PMID Year
Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET. 61
33615670 2021
Reassessing the impact of tumor size on operative approach in adrenocortical carcinoma. 61
33577722 2021
Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization. 61
33687146 2021
Rare but serious cause for hypokalaemia and hypertension. 61
33664034 2021
Steroid sulfation in adrenal tumors. 61
33739426 2021
Adrenal tumors of different types with or without tumor thrombus invading the inferior vena cava: An evaluation of 33 cases. 61
33773281 2021
Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study. 61
33075802 2021
Delayed identification of adolescent adrenal cortical carcinoma initially diagnosed as polycystic ovary syndrome. 61
33775909 2021
Thermal ablation in adrenal disorders: a discussion of the technology, the clinical evidence and the future. 61
33741778 2021
Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells. 61
33810240 2021
Approach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomas. 61
33709971 2021
A case of adrenocortical adenoma harboring venous thrombus mimicking adrenal malignancy. 61
33658437 2021
Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma. 61
33221947 2021
Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma. 61
33725886 2021
11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool. 61
33570111 2021
11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool. 61
33340399 2021
11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool. 61
33508108 2021
Preoperative Detection of Liver Involvement by Right-Sided Adrenocortical Carcinoma Using CT and MRI. 61
33807178 2021
Adrenocortical Carcinoma. 61
33802418 2021
Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. 61
33807024 2021
Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. 61
33809752 2021
Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis. 61
33667214 2021
A rare association of two endocrine tumours: non-functional oncocytic adrenocortical carcinoma and Papillary thyroid carcinoma. 61
33675218 2021
Revisiting Cushing's Syndrome, Milder Forms Are Now a Common Occurrence- A Single Center Cohort of 76 Subjects. 61
33652108 2021
HOX genes promote cell proliferation and are potential therapeutic targets in adrenocortical tumours. 61
33214683 2021
A rare case of right shoulder pain. 61
33568404 2021
Stereoisomeric selectivity in the endocrine-disrupting potential of cypermethrin using in vitro, in vivo, and in silico assays. 61
33677314 2021
A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. 61
33285287 2021
Cystic adrenal lesions: A report of five cases. 61
33295135 2021
Diabetes mellitus and hyperglycemia are associated with inferior oncologic outcomes in adrenocortical carcinoma. 61
33521844 2021
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. 61
33166271 2021
Diagnostic dilemma for an adrenal mass: perivascular epithelioid cell neoplasm versus adrenocortical carcinoma. 61
33547853 2021
[Myxoid variant of adrenocortical carcinoma]. 61
33549334 2021
Cushing's syndrome and bone metastases as the manifestation of adrenocortical carcinoma. 61
33624953 2021
Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology. 61
33604708 2021
Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging. 61
33578929 2021
The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives. 61
33578890 2021
Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. 61
33586069 2021
Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data. 61
33626208 2021
Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. 61
33279475 2021
Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes. 61
33564960 2021
Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. 61
32996176 2021
Current Status and Future Targeted Therapy in Adrenocortical Cancer. 61
33732213 2021
Adrenocortical tumours in children: a review of surgical management at a tertiary care centre. 61
33438328 2021
Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. 61
33677483 2021
CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis. 61
33680972 2021
Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. 61
33086388 2021
Bilateral adrenal hypermetabolism with 18F-FDG PET/CT as an incidental finding in suspected recurrence of adrenocortical carcinoma. 61
33446456 2021
Adrenal Surgery for Synchronously Metastatic Adrenocortical Carcinoma: A Population-Based Analysis. 61
33481081 2021
Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome. 61
33185660 2021

Variations for Adrenal Cortical Adenocarcinoma

Expression for Adrenal Cortical Adenocarcinoma

Search GEO for disease gene expression data for Adrenal Cortical Adenocarcinoma.

Pathways for Adrenal Cortical Adenocarcinoma

Pathways related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
12.31 KCNK9 KCNK7 KCNK15
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 11.79 SPRY2 SH3KBP1 RPS6KA1
8 11.67 SPRY2 SPRY1 SH3KBP1
Show member pathways
Show member pathways
11.53 KCNK9 KCNK7 KCNK15
Show member pathways
11.45 RPS6KA6 RPS6KA1
12 11.2 SPRY2 RPS6KA1
13 11.12 RPS6KA6 RPS6KA1
Show member pathways
15 11.03 SPRY2 SH3KBP1
16 10.98 SPRY2 SPRY1 RPS6KA1 BAD

GO Terms for Adrenal Cortical Adenocarcinoma

Biological processes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 potassium ion transport GO:0006813 9.61 KCNK9 KCNK7 KCNK15
2 potassium ion transmembrane transport GO:0071805 9.58 KCNK9 KCNK7 KCNK15
3 regulation of signal transduction GO:0009966 9.56 SPRY2 SPRY1
4 negative regulation of GTPase activity GO:0034260 9.55 SPRY2 SPRY1
5 negative regulation of MAP kinase activity GO:0043407 9.54 SPRY2 SPRY1
6 negative regulation of epithelial to mesenchymal transition GO:0010719 9.52 SPRY2 SPRY1
7 establishment of mitotic spindle orientation GO:0000132 9.51 SPRY2 SPRY1
8 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 SPRY2 SPRY1 RPS6KA6
9 negative regulation of Ras protein signal transduction GO:0046580 9.49 SPRY2 SPRY1
10 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.48 SPRY2 SPRY1
11 animal organ development GO:0048513 9.46 SPRY2 SPRY1
12 bud elongation involved in lung branching GO:0060449 9.37 SPRY2 SPRY1
13 negative regulation of lens fiber cell differentiation GO:1902747 9.26 SPRY2 SPRY1
14 negative regulation of neurotrophin TRK receptor signaling pathway GO:0051387 9.16 SPRY2 SPRY1
15 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.13 SPRY2 SPRY1 SH3KBP1
16 stabilization of membrane potential GO:0030322 8.8 KCNK9 KCNK7 KCNK15

Molecular functions related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium channel activity GO:0005267 9.33 KCNK9 KCNK7 KCNK15
2 ribosomal protein S6 kinase activity GO:0004711 8.96 RPS6KA6 RPS6KA1
3 potassium ion leak channel activity GO:0022841 8.8 KCNK9 KCNK7 KCNK15

Sources for Adrenal Cortical Adenocarcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....